Tower Research Capital LLC TRC Boosts Position in DENTSPLY SIRONA Inc. (NASDAQ:XRAY)

Tower Research Capital LLC TRC lifted its holdings in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report) by 602.3% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 26,372 shares of the medical instruments supplier's stock after acquiring an additional 22,617 shares during the period. Tower Research Capital LLC TRC's holdings in DENTSPLY SIRONA were worth $501,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of the stock. Nordea Investment Management AB boosted its holdings in shares of DENTSPLY SIRONA by 245.0% in the 4th quarter. Nordea Investment Management AB now owns 251,556 shares of the medical instruments supplier's stock valued at $4,754,000 after acquiring an additional 178,639 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in DENTSPLY SIRONA by 206.3% in the third quarter. JPMorgan Chase & Co. now owns 1,847,389 shares of the medical instruments supplier's stock valued at $49,990,000 after purchasing an additional 1,244,326 shares during the last quarter. Bank of New York Mellon Corp grew its position in DENTSPLY SIRONA by 27.9% during the 4th quarter. Bank of New York Mellon Corp now owns 2,403,110 shares of the medical instruments supplier's stock worth $45,611,000 after purchasing an additional 523,692 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of DENTSPLY SIRONA by 1.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,101,133 shares of the medical instruments supplier's stock valued at $39,880,000 after buying an additional 35,360 shares during the last quarter. Finally, Barclays PLC lifted its holdings in shares of DENTSPLY SIRONA by 21.8% in the 3rd quarter. Barclays PLC now owns 306,809 shares of the medical instruments supplier's stock valued at $8,301,000 after buying an additional 54,920 shares during the period. Institutional investors and hedge funds own 95.70% of the company's stock.

Insider Buying and Selling

In other DENTSPLY SIRONA news, Director Gregory T. Lucier bought 15,142 shares of the firm's stock in a transaction on Monday, March 3rd. The shares were acquired at an average cost of $16.51 per share, with a total value of $249,994.42. Following the purchase, the director now directly owns 81,971 shares of the company's stock, valued at $1,353,341.21. This trade represents a 22.66 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 0.52% of the stock is currently owned by company insiders.

DENTSPLY SIRONA Price Performance

NASDAQ XRAY traded down $0.07 during mid-day trading on Monday, hitting $14.02. The stock had a trading volume of 542,285 shares, compared to its average volume of 2,948,082. The firm's 50 day moving average is $14.59 and its 200 day moving average is $17.88. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.25 and a quick ratio of 0.84. The stock has a market capitalization of $2.79 billion, a price-to-earnings ratio of -6.77, a PEG ratio of 1.80 and a beta of 0.92. DENTSPLY SIRONA Inc. has a twelve month low of $12.16 and a twelve month high of $29.13.

DENTSPLY SIRONA Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, April 11th. Stockholders of record on Friday, March 28th were paid a $0.16 dividend. This represents a $0.64 annualized dividend and a dividend yield of 4.57%. The ex-dividend date of this dividend was Friday, March 28th. DENTSPLY SIRONA's dividend payout ratio is currently -14.07%.

Analyst Ratings Changes

XRAY has been the topic of several analyst reports. Morgan Stanley lowered DENTSPLY SIRONA from an "overweight" rating to an "equal weight" rating and set a $14.00 target price on the stock. in a report on Tuesday, April 15th. Mizuho decreased their target price on shares of DENTSPLY SIRONA from $21.00 to $18.00 and set a "neutral" rating for the company in a research note on Thursday, March 13th. Piper Sandler dropped their price target on shares of DENTSPLY SIRONA from $20.00 to $16.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 30th. Evercore ISI reiterated an "in-line" rating and issued a $20.00 price objective on shares of DENTSPLY SIRONA in a research report on Tuesday, January 7th. Finally, Wells Fargo & Company dropped their target price on DENTSPLY SIRONA from $20.00 to $19.00 and set an "equal weight" rating on the stock in a research report on Friday, February 28th. Thirteen equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat, DENTSPLY SIRONA presently has a consensus rating of "Hold" and an average target price of $21.25.

DENTSPLY SIRONA Profile

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.